XML 67 R54.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

Commitments and Contingent Liabilities - Narrative (Details) $ in Millions | 1 Months Ended | 3 Months Ended | 12 Months Ended |  |  |  |
--- | --- | --- | --- | --- | --- | --- | ---
Jul. 31, 2024 USD ($) | May 30, 2024 USD ($) | Dec. 31, 2021 USD ($) | Jun. 30, 2024 USD ($) case distributor subdivision state | Jun. 30, 2023 USD ($) | Mar. 31, 2024 USD ($) plaintiff | Nov. 30, 2022 USD ($) | Jul. 31, 2020 state | Mar. 31, 2018 USD ($) | Mar. 31, 2017 USD ($)
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |
Claims and litigation charges |  |  |  | $ 112 | $ 0 |  |  |  |  |
Opioid stewardship act, New York, annual surcharge |  |  |  |  |  |  | $ 42 |  | $ 100 | $ 100
Proceeds from legal settlements |  | $ 90 |  | 90 | $ 118 |  |  |  |  |
National Prescription Opioid Litigation |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |
Claims and litigation charges |  |  |  | 114 |  | $ 149 |  |  |  |
National Prescription Opioid Litigation | U.S. Pharmaceutical |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |
Claims and litigation charges |  |  |  | 57 |  | (74) |  |  |  |
National Prescription Opioid Litigation | Corporate Segment |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |
Claims and litigation charges |  |  |  | $ 57 |  | $ (75) |  |  |  |
National Prescription Opioid Litigation | United States |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |
Complaints filed against the entity | case |  |  |  | 400 |  |  |  |  |  |
National Prescription Opioid Litigation | Canada |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |
Complaints filed against the entity | case |  |  |  | 4 |  |  |  |  |  |
National Prescription Opioid Litigation | An individual | United States |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |
Complaints filed against the entity | case |  |  |  | 1 |  |  |  |  |  |
National Prescription Opioid Litigation | An individual | Canada |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |
Complaints filed against the entity | case |  |  |  | 1 |  |  |  |  |  |
New York Opioid Tax Surcharge | U.S. Pharmaceutical |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |
Loss contingency accrual, payments |  |  | $ 26 |  |  |  |  |  |  |
National Prescription Opioid Litigation |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |
Number of other national distributors named in suit | distributor |  |  |  | 2 |  |  |  |  |  |
Number of states in which court cases are pending | state |  |  |  | 48 |  |  |  |  |  |
Loss contingency, number of cases dismissed | case |  |  |  | 2,300 |  |  |  |  |  |
Portion of settlement award to be used by state and local government for remediation (percent) |  |  |  | 85.00% |  |  |  |  |  |
Loss contingency, claims settled, number of jurisdictions not participating in settlement | subdivision |  |  |  | 1 |  |  |  |  |  |
Number of plaintiffs | plaintiff |  |  |  |  |  | 1 |  |  |  |
National Prescription Opioid Litigation | State of Alabama and Subdivisions |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |
Settlement payment |  |  |  | $ 61 |  |  |  |  |  |
Award payable under proposed framework |  |  |  | $ 113 |  |  |  |  |  |
National Prescription Opioid Litigation | Native American Tribes Other Than Cherokee Nation |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |
Litigation settlement, amount awarded to other party, percentage of total settlement to be used to remediate damages |  |  |  | 0.85 |  |  |  |  |  |
National Prescription Opioid Litigation | Settling Governmental Entities and Cherokee Nation | Settled Litigation |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |
Settlement payment |  |  |  | $ 0 |  |  |  |  |  |
National Prescription Opioid Litigation | Settling Governmental Entities and Cherokee Nation | Settled Litigation | Subsequent Event |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |
Settlement payment | $ 500 |  |  |  |  |  |  |  |  |
National Prescription Opioid Litigation | Three Largest U.S. Pharmaceutical Distributors |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |
Settlement payment |  |  |  | 1,500 |  |  |  |  |  |
Award payable under proposed framework |  |  |  | 6,300 |  |  |  |  |  |
National Prescription Opioid Litigation | Three National Pharmaceutical Distributors | State of West Virginia and Subdivisions |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |
Settlement payment |  |  |  | 53 |  |  |  |  |  |
Award payable under proposed framework |  |  |  | 99 |  |  |  |  |  |
National Prescription Opioid Litigation | Three National Pharmaceutical Distributors | Cherokee Nation |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |
Settlement payment |  |  |  | 84 |  |  |  |  |  |
National Prescription Opioid Litigation | Three National Pharmaceutical Distributors | Native American Tribes Other Than Cherokee Nation |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |
Award payable under proposed framework |  |  |  | $ 112 |  |  |  |  |  |
United States ex rel. Hart v. McKesson Corporation, et al., 15-cv-00903-RA |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |
Number of states filed on behalf of | state |  |  |  |  |  |  |  | 27 |  |

X
- Definition Litigation Settlement, Amount Awarded to Other Party, Percentage of Total Settlement to Be Used to Remediate Damages + References No definition available. + Details
Name: | mck_LitigationSettlementAmountAwardedToOtherPartyPercentageOfTotalSettlementToBeUsedToRemediateDamages
Namespace Prefix: | mck_
Data Type: | xbrli:pureItemType
Balance Type: | na
Period Type: | instant

X
- Definition Litigation Settlement, Award Amount To Be Used by State and Local Government + References No definition available. + Details
Name: | mck_LitigationSettlementAwardAmountToBeUsedByStateAndLocalGovernment
Namespace Prefix: | mck_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Loss Contingency, Claims Settled, Number Of Jurisdictions Not Participating In Settlement + References No definition available. + Details
Name: | mck_LossContingencyClaimsSettledNumberOfJurisdictionsNotParticipatingInSettlement
Namespace Prefix: | mck_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Loss Contingency, Number Of Cases Dismissed + References No definition available. + Details
Name: | mck_LossContingencyNumberOfCasesDismissed
Namespace Prefix: | mck_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Loss Contingency, Number of Other Defendants + References No definition available. + Details
Name: | mck_LossContingencyNumberOfOtherDefendants
Namespace Prefix: | mck_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Loss Contingency, Number of States Filed On Behalf Of + References No definition available. + Details
Name: | mck_LossContingencyNumberOfStatesFiledOnBehalfOf
Namespace Prefix: | mck_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Loss Contingency, Number of States + References No definition available. + Details
Name: | mck_LossContingencyNumberofStates
Namespace Prefix: | mck_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Opioid Stewardship Act, New York, Annual Surcharge + References No definition available. + Details
Name: | mck_OpioidStewardshipActNewYorkAnnualSurcharge
Namespace Prefix: | mck_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 + Details
Name: | us-gaap_GainLossRelatedToLitigationSettlement
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount awarded to other party in judgment or settlement of litigation. + References No definition available. + Details
Name: | us-gaap_LitigationSettlementAmountAwardedToOtherParty
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 27 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details
Name: | us-gaap_LossContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of cash outflow reducing loss contingency liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details
Name: | us-gaap_LossContingencyAccrualPayments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of plaintiffs that have filed claims pertaining to a loss contingency. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 + Details
Name: | us-gaap_LossContingencyNumberOfPlaintiffs
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of pending claims pertaining to a loss contingency. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 + Details
Name: | us-gaap_LossContingencyPendingClaimsNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The amount of cash paid for the settlement of litigation or for other legal issues during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details
Name: | us-gaap_PaymentsForLegalSettlements
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Cash received for the settlement of litigation during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details
Name: | us-gaap_ProceedsFromLegalSettlements
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_LossContingenciesByNatureOfContingencyAxis=mck_NationalPrescriptionOpiateLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mck_USPharmaceuticalSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_CA
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mck_IndividualClaimantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LossContingenciesByNatureOfContingencyAxis=mck_NewYorkOpioidTaxSurchargeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=mck_NationalPrescriptionOpiateLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mck_StateOfAlabamaAndSubdivisionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mck_NativeAmericanTribesOtherThanCherokeeNationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mck_SettlingGovernmentalEntitiesAndCherokeeNationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=mck_ThreeLargestUSPharmaceuticalDistributorsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=mck_ThreeNationalPharmaceuticalDistributorsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mck_StateOfWestVirginiaAndSubdivisionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mck_CherokeeNationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=mck_UnitedStatesExRelHartVMcKessonCorporationEtAl15Cv00903RAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |